[Clinical trials on expanded indication of ESD in Japan]

Previous | List | Next


2012³â 12¿ù 8ÀÏ 20th Seoul International Cancer Symposium¿¡ ´Ù³à¿Ô½À´Ï´Ù. Ogata¶ó´Â ÀϺ» ¿Ü°úÀǻ簡 ESD¿¡ ´ëÇÏ¿© °­ÀÇÇÏ´Â °ÍÀ» µé¾ú½À´Ï´Ù. ÀϺ»¿¡´Â ³»½Ã°æÇÏ´Â ¿Ü°úÀǻ簡 ¸¹½À´Ï´Ù. Dr. GotodaÀÇ 3³â ÈĹè¶ó°í ÀÚ½ÅÀ» ¼Ò°³ÇÑ Dr. OgataÀÇ °­ÀÇ Áß Èï¹Ì·Î¿î ºÎºÐÀº ÀϺ»ÀÇ clinical trail¿¡ ´ëÇÑ ¼Ò°³¿´½À´Ï´Ù.

- JCOG 0607: phase 2 trial of ESD for expanded indication

- JCOG 1009/1010: phase 2 rial of EGD for undifferentiated type of EGC

JCOG 0607Àº ȯÀÚµî·ÏÀÌ ³¡³µ°í 2015³â °æ °á°ú°¡ ¹ßÇ¥µÉ ¿¹Á¤ÀÌ°í, JCOG 1009/1010Àº ÇöÀç ȯÀÚ µî·Ï ÁßÀ̶ó°í ÇÕ´Ï´Ù. µÑ ´Ù phase 2 trial·Î control groupÀÌ ¾ø´Â single arm studyÀÔ´Ï´Ù. JCOG¿¡ ´ëÇÑ Á¤º¸´Â Japan Clinical Oncology Group ȨÆäÀÌÁö¸¦ Âü°íÇϱ⠹ٶø´Ï´Ù. ÀϺ»¾î·Î ¾º¿© ÀÖÁö¸¸ ChromeÀÇ Çѱ¹¸»·Î ¹ø¿ª ¼­ºñ½º¸¦ ÀÌ¿ëÇÏ¸é ½±°Ô ÀÐÀ» ¼ö ÀÖ½À´Ï´Ù.

±¹³»¿¡¼­ ¹ßÇ¥µÇ´Â ¸¹Àº µ¥ÀÌŸ°¡ retrospective studyÀÌ°í follow-up loss°¡ ¸¹´Ù´Â ¾àÁ¡ÀÌ ÀÖ½À´Ï´Ù. JCOG ¿¬±¸µéÀº ºñ·Ï randomized trialÀº ¾Æ´Ñ phage 2 trialÀ̶ó´Â ÇÑ°è´Â ÀÖÀ¸³ª, ÀüÇâÀûÀ¸·Î ȯÀÚ¸¦ µî·ÏÇÏ¿© Àå±â °üÂûÇÑ´Ù´Â Á¡¿¡¼­ ÀÇÀÇ°¡ ÀÖ¾î º¸ÀÔ´Ï´Ù. °á°ú°¡ ±â´Ù·ÁÁý´Ï´Ù.

[Home]